RSS Feeds
Effects of Enalapril on Erythrocytosis after Renal Transplantation
- Robert S. Gaston, MD;
- Bruce A. Julian, MD;
- Arnold G. Diethelm, MD; and
- John J. Curtis, MD
Excerpt
Erythrocytosis afflicts 4% to 17% of renal allograft recipients. It appears most often within the first year after transplant, usually in patients with excellent graft function, and is associated with an increased risk for thromboembolic events (1). Although the pathophysiology is poorly defined, it may relate to excess production of erythropoietin by native kidneys (2). The standard therapy is serial phlebotomy (1), but no treatment has proved optimal. A recent report of enalapril-associated anemia in renal transplant recipients (3) led to a trial of this agent as therapy for post-transplant erythrocytosis.
Methods Twelve renal allograft recipients (mean age, 39 ±
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
Acknowledgment: The authors thank Catherine Barker, RN, for technical support.
Article and Author Information
-
From the University of Alabama Medical Center, Birmingham, Alabama. For current author addresses, see end of text.
-
Current Author Addresses: Drs. Gaston, Julian, and Curtis: Division of Nephrology, University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294.
Dr. Diethelm: Department of Surgery, University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294.
